Epic’s Life Sciences program is released with the aim to connect providers, pharmaceutical companies, and medical device manufacturers to recruit research participants, expand clinical trial access, and to speed up therapy development.
A fleet of legal professionals offers advice and perspective on important considerations when harnessing artificial intelligence and real-world evidence.
Experts from the health information specialist explain how the use of RWD and RWE has helped speed up and improve the development of therapies and vaccines.
Impel Pharmaceuticals’ Trudhesa treatment, paired with its Precision Olfactory Delivery system, reportedly shows promise to women suffering from the condition.
The Digital Medicine Society is offering a library of resources to help promote the use of nocturnal scratch as an endpoint for the troubling skin condition.
The clinical-stage biotechnology company is working on the advancement of a treatment for a blood vessel disorder that it licensed from the other company
The companies will work together to help clients connect information sources, giving stakeholders a better overview of the clinical patient experience.
Bioprocessing 4.0 and digitalization is all about embracing new technologies to enable faster, smoother and more efficient biomanufacturing. And that also requires embracing a new mindset.
With the purchase, the company is looking to advance its plans to connect with potential trial participants and spread awareness of study participation.
A representative from the biometric contract research organization explains how taking a ‘patient comes first’ attitude can lead to a range of improvements.
This month’s announcements of appointments, acquisitions, new hires, and other news include Standigm, Astellas Pharma, Trialbee, and other key companies.
In response to rising demand for inhalable treatments geard toward respiratory conditions, the company is adding capabilities and capacity at its Tampa site.
The physIQ monitoring platform will be used to evaluate an inhaled treatment, developed by InCarda, that is intended to treat atrial fibrillation patients.
The company has landed funding from the Bill and Melinda Gates Foundation for research and development on a prototype of a refillable contraceptive solution.
The company reports dosing of the first subject in a Phase IIa proof-of-concept study investigating a drug for an autism spectrum disorder related condition.
The National Institutes of Health grant to AVM Biotechnology will be used to evaluate a drug to treat non-Hodgkin’s lymphoma combined with standard of care.
The pharmaceutical company and the artificial intelligence pathology specialist will focus on translational research in oncology, fibrosis, and immunology.
A leader suggests considering patient views and needs all along the clinical development path reaps a number of benefits, including time and cost savings.
This month’s news on technology, partnerships, expansions, and more includes items from IQVIA, Almac Group, Signant Health, Lonza, and other key companies.
The group has introduced a downloadable guide, interactive quiz, and other tools to inform patients from underrepresented communities about trial participation.
A leader from the trial financial management specialist suggests apps used in trials could be adjusted to better suit patients, sites and other stakeholders.
The pharmaceutical company has completed acquisition of Turning Point Therapeutics, a company specializing in precision medicine solutions for cancer patients.
The National Institute for Health and Care Excellence is weighing the viability of PD Neurotechnology’s PDMonitor system for Parkinson’s disease patients.
The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast cancer.
An expert from the clinical insight specialist shares how predictive analytics could reveal info about medication adherence, disease progression, and more.
Signant Health has partnered with the software company o connect its platforms for the management of clinical supply chain inventory, labels, and content.
The pharmaceutical company has inked a strategic collaboration with the drug discovery firm, centering on uncovering novel targets in Alzheimer’s disease.
A leader from the behavioral science specialist shares ways to use precision engagement and other methods to increase patient adherence in clinical studies.
After scientists and reporters raised red flags about a study, Cassava Sciences is being accused of falsifying data in pursuit of an Alzheimer’s treatment.
The two companies are collaborating to generate subject data sets designed to help users find insights that can speed up research and improve patient care.
This month’s announcements of appointments, partnerships, expansions, and mergers include Curia, Thread, TFF Pharmaceuticals, and other notable companies.
An expert from the trial tech firm explains how the 21st Century Cures Act and other recent regulatory advancements can elevate clinical data registries.
The pharmaceutical company has forged a partnership with the life-sciences tech firm in an effort to elevate data collection and speed up clinical studies.
A survey by SubjectWell indicates that having Spanish-speaking research personnel increases interest in trial participation among Latino potential patients.
With updates to the Guideline for Good Clinical Practice Advancements on the horizon, an industry expert offers some perspective on what might be ahead.
The CRO and DTx specialist are joining forces to conduct a hybrid clinical trial of a potential digital therapeutic that is aimed at treating fibromyalgia.
A joint study conducted by analysts from Medable and the Center for the Study of Drug Development points toward shorter cycle times, cost savings, and more.
During the World Orphan Drug Congress, a co-founder of the CRO outlined how patient perspective can be vital to better results in rare-disease research.
The gathering, convened by patient advocacy group Fight Colorectal Cancer, responded to President Biden’s call to improve screening and treatment options.
During the Decentralized Trial Technology event, experts from CVS Health, University of Chicago, and ACRP shared insight on what can increase DCT success.
A leader from the CRO discusses how capturing the perspective of trial participants can help ensure development of treatments that meet the patients’ needs.
This month’s announcements on new products, tech partnerships, and more includes DiMe, Evonik, Advarra, Curebase, ObvioHealth, and other notable companies.
The biotechnology company has reported its candidate for treating amyotrophic lateral sclerosis patients has shown promising results in an early-phase study.
The research institutions are joining on a community-based collaborative initiative to work toward greater study inclusion, supported by funding from PhRMA.
Epistemic AI, Cincinnati Children’s Hospital Medical Center, and Boomer Esiason Foundation are working together to advance research into the rare disease.
The CRO and medical genetics company will collaborate to accelerate trials centered on rare diseases, using real-world data and genetic testing technology.
The Foundation for Sarcoidosis Research hosted more than 50 agency leaders in a session that addressed patient concerns in research, care, and diagnosis.
